Overview

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

Status:
Recruiting

Trial end date:
2023-01-23

Target enrollment:

Participant gender:

Summary

To evaluate the feasibility of administering HCQ, EVE or the combination in patients who have completed primary therapy for breast cancer and harbor bone marrow disseminated tumor cells.

Phase:

Phase 2

Details

Lead Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Treatments:

Everolimus
Hydroxychloroquine
Sirolimus